Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...

Better lung function, expressed as higher forced vital capacity (FVC), is associated with a reduced risk for the onset of heart disease, diabetes, and stroke over a follow-up period of approximately ...

Research based on eight cohorts from Europe and Australia, provides new guidelines for assessing and monitoring lung health throughout life Until now, it was thought that lung function increased until ...

In the reports on vital capacity in the literature, instructions to the patients were not described in detail. In our experience variations in the results of serial determinations were traced in many ...

A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and ...

Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...

Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the efficacy of nintedanib ...

A study has shown how lung capacity evolves from childhood to old age. Until now, it was thought that lung function increased until it peaked at around 20-25 years of age, after which it stabilized.